Ubs Group Ag Infla Rx N.V. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Infla Rx N.V. stock. As of the latest transaction made, Ubs Group Ag holds 8,095 shares of IFRX stock, worth $6,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,095

Holding current value

$6,718

% of portfolio

0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.73 - $1.85 $5,909 - $14,975	8,095 New	8,095 $6,000
Q4 2024 Feb 14, 2025	BUY	$1.38 - $2.64 $93,068 - $178,044	67,441 New	67,441 $167,000
Q3 2023 Nov 09, 2023	BUY	$2.66 - $4.33 $1,231 - $2,004	463 New	463 $1,000
Q4 2022 Feb 08, 2023	SELL	$2.11 - $3.25 $10,248 - $15,785	-4,857 Reduced 90.6%	504 $1,000
Q3 2022 Nov 10, 2022	BUY	$1.32 - $3.14 $7,076 - $16,833	5,361 New	5,361 $14,000
Q2 2022 Aug 10, 2022	SELL	$0.78 - $1.9 $1,935 - $4,713	-2,481 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.83 - $4.48 $3,680 - $9,009	-2,011 Reduced 44.77%	2,481 $5,000
Q4 2021 Feb 14, 2022	SELL	$2.35 - $5.58 $1,229 - $2,918	-523 Reduced 10.43%	4,492 $21,000
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.03 $8,482 - $11,423	3,770 Added 302.81%	5,015 $13,000
Q2 2021 Aug 13, 2021	SELL	$2.72 - $4.04 $14,372 - $21,347	-5,284 Reduced 80.93%	1,245 $4,000
Q1 2021 May 12, 2021	BUY	$3.62 - $6.34 $16,590 - $29,056	4,583 Added 235.51%	6,529 $25,000
Q4 2020 Feb 11, 2021	BUY	$3.82 - $5.32 $294 - $409	77 Added 4.12%	1,946 $10,000
Q3 2020 Nov 12, 2020	BUY	$3.7 - $5.47 $1,835 - $2,713	496 Added 36.13%	1,869 $8,000
Q2 2020 Jul 31, 2020	SELL	$4.59 - $8.96 $4,645 - $9,067	-1,012 Reduced 42.43%	1,373 $6,000
Q1 2020 May 01, 2020	BUY	$2.65 - $6.08 $6,320 - $14,500	2,385 New	2,385 $9,000
Q4 2019 Feb 14, 2020	SELL	$2.2 - $4.54 $2,472 - $5,102	-1,124 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.47 - $3.51 $2,776 - $3,945	1,124 New	1,124 $3,000
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $1,373 - $23,172	-449 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$31.16 - $48.62 $13,990 - $21,830	449 New	449 $17,000
Q4 2018 Feb 14, 2019	SELL	$23.33 - $36.37 $56,971 - $88,815	-2,442 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $77,428 - $92,365	-2,639 Reduced 51.94%	2,442 $84,000
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $136,704 - $207,382	5,002 Added 6331.65%	5,081 $164,000
Q1 2018 May 15, 2018	SELL	$20.21 - $32.0 $20,088 - $31,808	-994 Reduced 92.64%	79 $2,000
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $15,612 - $25,741	1,073	1,073 $22,000

Others Institutions Holding IFRX

# of Institutions

Shares Held

17.5M

Call Options Held

32.7K

Put Options Held

Suvretta Capital Management, LLC New York, NY

6.48M
Shares

$5.38 Million
0.18% of portfolio
683 Capital Management, LLC New York, NY

2.48M
Shares

$2.05 Million
0.15% of portfolio
Ra Capital Management, L.P. Boston, MA

1.97M
Shares

$1.64 Million
0.03% of portfolio
Eversept Partners, LP New York, NY

1.64M
Shares

$1.36 Million
0.13% of portfolio
Woodline Partners LP San Francisco, CA

751K
Shares

$623,551
0.0% of portfolio

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $36.7M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account